Moreover, as the research community discovers more BRCA2-related genes (such as the Fanconi Anemia genes) and pathways disrupted in cancers (78) two new opportunities will be: (i) to select patients’ tumors that would be optimal for a synthetic lethal approach using PARP inhibitors and (ii) defining new targets within this pathway (79). This evidence concerns the gene BRCA2 and Fanconi anemia.